Literature DB >> 9219187

Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments.

D G Fryback1, W F Lawrence.   

Abstract

The scale of health state quality that should be used to compute quality-adjusted life years (QALYs) ranges from 0 (death) to 1.0 (excellent health); this is called the "Q" scale. But many cost-utility analyses (CUAs) in the literature use the upper anchor of the scale to denote only the absence of the particular health condition under investigation, and weight the disease state proportional to this endpoint; these are called "q" scales. Computations using q-scale health-state weights ignore the fact that the average patient is still subject to chronic and acute conditions comorbid with the condition being analyzed; the absence of a particular condition is not in general the same as excellent health, i.e., the Q scale is longer than a q scale. CUAs based on q scales yield "qALYs." Incremental $/qALY ratios are generally lower than $/QALY ratios; in the example presented, $/qALY must be inflated by about 15% to yield $/QALY. Other CUAs correctly weight disease states using the Q scale, but erroneously assign a quality weight of 1.0 to absence of the disease in the CUA computations. The results of such analyses are called "NP-QALYs," as the correction factor to compute QALYs is not a simple proportional adjustment. The authors suggest that analysis doing cost-utility analyses without access to primary data from treated patients use average age-specific health-related quality-of-life weights from population-based studies to represent the state of not having a particular disease. Consumers of CUAs should closely examine the nature of the QALYs in any published analyses before making decisions based on their results.

Entities:  

Mesh:

Year:  1997        PMID: 9219187     DOI: 10.1177/0272989X9701700303

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  26 in total

1.  Evaluating the benefits of increasing measles immunization rates.

Authors:  J Zwanziger; P G Szilagyi; P Kaul
Journal:  Health Serv Res       Date:  2001-10       Impact factor: 3.402

2.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

Review 3.  Resource allocation, social values and the QALY: a review of the debate and empirical evidence.

Authors:  David L B Schwappach
Journal:  Health Expect       Date:  2002-09       Impact factor: 3.377

4.  A meta-analysis of quality-of-life estimates for stroke.

Authors:  Tammy O Tengs; Ting H Lin
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 5.  Willingness to pay for a QALY: theoretical and methodological issues.

Authors:  Dorte Gyrd-Hansen
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients.

Authors:  Karen E Bremner; George Tomlinson; Murray D Krahn
Journal:  Qual Life Res       Date:  2007-10-03       Impact factor: 4.147

7.  Validity and feasibility of the use of condition-specific outcome measures in economic evaluation.

Authors:  Elly A Stolk; Jan J V Busschbach
Journal:  Qual Life Res       Date:  2003-06       Impact factor: 4.147

8.  Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea.

Authors:  SeungJin Bae; Eun Young Bae; Sang Hee Lim
Journal:  Patient       Date:  2014       Impact factor: 3.883

9.  Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.

Authors:  Malek B Hannouf; Bin Xie; Muriel Brackstone; Gregory S Zaric
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

10.  Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.

Authors:  Mehmet U S Ayvaci; Jinghua Shi; Oguzhan Alagoz; Sam J Lubner
Journal:  Med Decis Making       Date:  2013-01-11       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.